Movano Health to Participate in Bernstein CGM Disruptors Conference, BTIG Digital Health Forum and Benchmark Discovery Conference

PLEASANTON, Calif., Nov. 16, 2022 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, today announced it will be participating at several upcoming investor-focused events. As part of its presentation, Movano Health's management team will provide an update on the Company's progress toward commercializing its smart ring and its single chip solution, which is the smallest ever radio-frequency enabled integrated circuit designed for blood pressure or glucose monitoring systems.

Details for the conferences are below:

• Bernstein 2^nd Annual CGM Disruptors Conference, which is being held virtually on November 18, 2022
• BTIG Digital Health Forum, which is being held virtually on November 21, 2022
• Benchmark Company's 11^th Annual Discovery One-on-One Investor Conference at the New York Athletic Club on December 1, 2022

All of the conferences are intended for prospective and existing clients and are invite-only. For more information about Movano Health, please visit https://movanohealth.com.

Founded in 2018, Movano Inc. (NASDAQ:MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health's end-to-end solutions will soon enable consumers, caretakers and healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage their health. For more information, visit www.movanohealth.com. 

This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development and features, product releases, clinical trial and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. 

SOURCE Movano